
## **Supplement 1 - Supplemental Figures and Tables**

McCreary EK, Lemon L, Megli C, et al. Monoclonal antibodies for treatment of SARS-CoV-2 infection during pregnancy

#### **Table of Contents**

eFigure 1.	Forest Plot of Adjusted Risk Ratios for COVID-19 Associated Outcome from Propensity Score Adjusted Analysis, by Subgroups					
eFigure 2.	Forest Plot of Adjusted Risk Ratios for Non-COVID-19 Associated Outcome from Propensity Score Adjusted Analysis, by Subgroups	3				
eFigure 3.	Cumulative Density Plot of Non-COVID-19 Related Outcome Events, Stratified by Monoclonal Antibody Treatment	4				
eFigure 4.	Histograms of Propensity Scores, Stratified by Monoclonal Antibody Treatment	5				
eFigure 5.	Love Plot of Standardized Percent Bias Across Covariates Before and After Propensity Score Matching					
eFigure 6.	Histograms of Cohort Accrual Over Time, Stratified by Monoclonal Antibody Treatment	7				
eFigure 7.	Histograms of Gestational Age at Index Date, Stratified by Monoclonal Antibody Treatment	8				
eTable 1.	Comparison of Characteristics of Pregnant mAb Treated vs Non-Treated Persons in Propensity Score-Matched Cohorts	9				
eTable 2.	Risk-Adjusted Frequency of COVID-19 Associated Outcome or Other Admission Within 28-days of SARS-CoV-2 positive Test or Monoclonal Antibody Infusion in Unvaccinated, Vaccinated, Obese and Non-Obese Pregnancies	10				
eTable 3.	Hypertensive Disorder at Delivery Identified by ICD Coding Documented During Delivery Admission	11				


eFigure 1. Forest Plot of Adjusted Risk Ratios for COVID-19 Associated Outcome from Propensity Score Adjusted Analysis, by Subgroups



First trimester= <14 weeks gestation Second trimester=14 weeks to <27 weeks gestation Third trimester= 27+ weeks gestation

Abbreviations: mAb: monoclonal antibodies


eFigure 2. Forest Plot of Adjusted Risk Ratios for Non-COVID-19 Associated Outcome from Propensity Score Adjusted Analysis, by Subgroups




First trimester= <14 weeks gestation Second trimester=14 weeks to <27 weeks gestation Third trimester= 27+ weeks gestation

Abbreviations: mAb: monoclonal antibodies

eFigure 3. Cumulative Density Plot of Non-COVID-19 Related Outcome Events, Stratified by Monoclonal Antibody Treatment




Red represents untreated, blue represents treated with monoclonal antibodies.




Red represents untreated, blue represents treated with monoclonal antibodies. Panel A represents a histogram of propensity scores for the full cohort (n=944). Panel B represents a histogram of propensity scores for the matched cohort (n=648).

## eFigure 5. Love Plot of Standardized Percent Bias Across Covariates Before and After Propensity Score Matching




Red circle represents % bias across covariates before propensity score matching. Blue diamond represents % bias across covariates after propensity score matching.



#### eFigure 6. Histograms of Cohort Accrual Over Time, Stratified by Monoclonal Antibody Treatment

Red represents untreated and blue represents treated with monoclonal antibodies. Panel A represents a histogram of accrual of the full cohort (n=944). Panel B represents a histogram of accrual for the propensity matched cohort (n=648).



eFigure 7. Histograms of Gestational Age at Index Date, Stratified by Monoclonal Antibody Treatment

Red represents untreated and blue represents treated with monoclonal antibodies. Panel A represents a histogram of gestational age at index date for the full cohort (n=944). Panel B represents a histogram of gestational age at index date for the propensity matched cohort (n=648).

All Patients	Treated	Non-Treated	p-value
648	324	324	
29.1 (25.2, 33.0)	29.0 (24.0, 33.0)	29.4 (25.8, 33.0)	0.37
494 (76.2%)	246 (75.9%)	248 (76.5%)	0.90
134 (20.7%)	67 (20.7%)	67 (20.7%)	
20 (3.1%)	11 (3.4%)	9 (2.8%)	
210 (32.4%)	104 (32.1%)	106 (32.7%)	0.87
10 (1.5%)	5 (1.5%)	5 (1.5%)	1.00
19 (2.9%)	8 (2.5%)	11 (3.4%)	0.48
211 (32.6%)	109 (33.6%)	102 (31.5%)	0.56
25 (3.9%)	14 (4.3%)	11 (3.4%)	0.54
0 (0)	0 (0)	0 (0.0)	NA
45 (6.9%)	19 (5.9%)	26 (8.0%)	0.28
40 (6.2%)	22 (6.8%)	18 (5.6%)	0.51
2 (03%)	0 (0.0%)	2 (0.6%)	0.16
24 (3.7%)	11 (3.4%)	13 (4.0%)	0.68
38 (5.9%)	20 (6.2%)	18 (5.6%)	0.74
76 (11.7%)	35 (10.8%)	41 (12.7%)	0.46
143 (22.1%)	91 (28.1%)	52 (16.0%)	0.001
40 (6.2%)	23 (7.1%)	17 (5.2%)	
222 (34.3%)	100 (30.9%)	122 (37.7%)	
243 (37.5%)	110 (34.0%)	133 (41.0%)	
	0 (0, 0)	0 (0, 0)	0.94
30.2 (26.6, 34.3)	31 (26.7, 33.6)	30 (26.4, 34.5)	0.77
180.5 (120.0, 228.5)	187 (125, 223.5)	175.5 (117.5, 231.5)	0.51
		( ()	
			0.19
. ,			0.80
6 (0.9%)	4 (1.2%)	2 (0.6%)	0.41
			0.65
			0.77
	648 29.1 (25.2, 33.0) 494 (76.2%) 134 (20.7%) 20 (3.1%) 210 (32.4%) 10 (1.5%) 19 (2.9%) 211 (32.6%) 25 (3.9%) 0 (0) 45 (6.9%) 40 (6.2%) 2 (03%) 24 (3.7%) 38 (5.9%) 76 (11.7%) 143 (22.1%) 40 (6.2%) 222 (34.3%) 243 (37.5%) 0 (0, 0)	648 324   29.1 (25.2, 33.0) 29.0 (24.0, 33.0)   494 (76.2%) 246 (75.9%)   134 (20.7%) 67 (20.7%)   20 (3.1%) 11 (3.4%)   210 (32.4%) 104 (32.1%)   10 (1.5%) 5 (1.5%)   19 (2.9%) 8 (2.5%)   211 (32.6%) 109 (33.6%)   25 (3.9%) 14 (4.3%)   0 (0) 0 (0)   45 (6.9%) 19 (5.9%)   40 (6.2%) 22 (6.8%)   2 (03%) 0 (0.0%)   24 (3.7%) 11 (3.4%)   38 (5.9%) 20 (6.2%)   76 (11.7%) 35 (10.8%)   143 (22.1%) 91 (28.1%)   40 (6.2%) 23 (7.1%)   222 (34.3%) 100 (30.9%)   243 (37.5%) 110 (34.0%)   0 (0,0) 0 (0,0)   30.2 (26.6, 34.3) 31 (26.7, 33.6)   180.5 (120.0, 228.5) 187 (125, 223.5)   102 (15.7%) 43 (13.3%)   248 (38.3%) 124 (38.3%)   223 (34.4%) 113 (34.9%)	648 $324$ $324$ $29.1 (25.2, 33.0)$ $29.0 (24.0, 33.0)$ $29.4 (25.8, 33.0)$ $494 (76.2%)$ $67 (20.7%)$ $67 (20.7%)$ $134 (20.7%)$ $67 (20.7%)$ $67 (20.7%)$ $20 (3.1%)$ $11 (3.4%)$ $9 (2.8%)$ $210 (32.4%)$ $104 (32.1%)$ $106 (32.7%)$ $10 (1.5%)$ $5 (1.5%)$ $5 (1.5%)$ $19 (2.9%)$ $8 (2.5%)$ $11 (3.4%)$ $211 (32.6%)$ $109 (33.6%)$ $102 (31.5%)$ $25 (3.9%)$ $14 (4.3%)$ $11 (3.4%)$ $0 (0)$ $0 (0)$ $0 (0.0)$ $45 (6.9%)$ $19 (5.9%)$ $26 (8.0%)$ $40 (6.2%)$ $22 (6.8%)$ $18 (5.6%)$ $2 (03%)$ $0 (0.0%)$ $2 (0.6%)$ $24 (3.7%)$ $11 (3.4%)$ $13 (4.0%)$ $38 (5.9%)$ $20 (6.2%)$ $18 (5.6%)$ $76 (11.7%)$ $35 (10.8%)$ $122 (37.7%)$ $143 (22.1%)$ $91 (28.1%)$ $52 (16.0%)$ $40 (6.2%)$ $23 (7.1%)$ $17 (5.2%)$ $222 (34.3%)$ $100 (30.9%)$ $122 (37.7%)$ $143 (22.1%)$ $91 (28.1%)$ $30 (26.4, 34.5)$ $180.5 (120.0, 228.5)$ $187 (125, 223.5)$ $175.5 (117.5, 231.5)$ $102 (15.7%)$ $43 (13.3%)$ $59 (18.2%)$ $248 (38.3%)$ $124 (38.3%)$ $124 (38.3%)$ $298 (46.0%)$ $157 (48.5%)$ $141 (43.5%)$ $223 (34.4%)$ $113 (34.9%)$ $110 (34.0%)$ $6 (0.9%)$ $4 (1.2%)$ $2 (0.6%)$ $81 (58.8%)$ $93 (59.6%)$ $188 (58.0%)$ $221 (34.1%)$ <

# eTable 1. Comparison of Characteristics of Pregnant mAb Treated vs. Non-treated Persons in Propensity Score-Matched Cohort

eTable 2. Risk-Adjusted Frequency of COVID-19 Associated Outcome or Other Admission Within 28-days of SARS-CoV-2 Positive Test or Monoclonal Antibody Infusion in Unvaccinated, Vaccinated, Obese, and Non-Obese Pregnancies

		Total Visits/	Total No. (%)	•	d 28-day COVID people (95%CI)	Risk Difference, per	Risk Ratio	
Model	No.	Treated Non-treated		Treated	Non-treated	100 people (95% CI)	(95% CI)	
Unvaccinated								
COVID-associated								
Crude	178	5/122 (4.1%)	6/56 (10.7%)	4.1 (0.58, 7.6)	10.7 (2.6, 18.8)	-6.6 (-15.5 <i>,</i> 2.2)	0.38 (0.12, 1.2)	
PS-adjusted	177	5/121 (4.1%)	6/56 (10.7%)	4.2 (0.61, 7.8)	10.2 (2.5, 18.0)	-6.0 (-14.5 <i>,</i> 2.5)	0.41 (0.13, 1.3)	
Other admission								
Crude	178	6/122 (4.9%)	0					
PS-adjusted	177	6/121 (5.0%)	0					
Vaccinated								
COVID-associated								
Crude	392	6/265 (2.3%)	1/127 (0.79%)	2.3 (0.47, 4.1)	0.79 (-0.75, 2.3)	1.5 (-0.88, 3.8)	2.9 (0.35, 23.6)	
PS-adjusted	387	6/262 (2.3%)	1/125 (0.8%)	2.6 (0.53, 4.7)	0.63 (-0.61, 1.9)	2.0 (-0.47, 4.4)	4.2 (0.48, 35.9)	
Other admission								
Crude	392	6/265 (2.3%)	2/127 (1.6%)	2.3 (0.47, 4.1)	1.6 (-0.59, 3.7)	0.69 (-2.1, 3.5)	1.4 (0.29, 7.0)	
PS-adjusted	387	6/262 (2.3%)	2/125 (1.6%)	2.3 (0.47, 4.2)	1.5 (-0.61, 3.7)	0.80 (-2.1, 3.7)	1.5 (0.30, 7.7)	
Obese								
COVID-associated								
Crude	569	13/337 (3.9%)	13/232 (5.6%)	3.9 (1.8, 5.9)	5.6 (2.6, 8.6)	-1.8 (-5.4, 1.9)	0.69 (0.33, 1.5)	
PS-adjusted	560	13/332 (3.9%)	12/228 (5.3%)	4.7 (2.2, 7.2)	4.3 (1.8, 6.7)	0.39 (-3.2, 4.0)	1.1 (0.49, 2.4)	
Other admission								
Crude	569	10/337 (3.0%)	2/232 (0.86%)	3.0 (1.2, 4.8)	0.86 (-0.33, 2.1)	2.1 (-0.06, 4.3)	3.4 (0.76, 15.6)	
PS-adjusted	560	10/332 (3.0%)	2/228 (0.88%)	3.0 (1.1, 4.9)	0.88 (-0.35, 2.1)	2.1 (-0.19, 4.4)	3.4 (0.71, 16.1)	
Non-Obese								
COVID-associated								
Crude	375	4/215 (1.9%)	4/160 (2.5%)	1.9 (0.05, 3.7)	2.5 (0.08, 4.9)	-0.6 (-3.7, 2.4)	0.74 (0.19, 2.9)	
PS-adjusted	370	4/215 (1.9%)	4/155 (2.6%)	2.1 (0.04, 4.1)	2.3 (0.03, 4.5)	-0.22 (-3.3, 2.8)	0.90 (0.22, 3.7)	
Other admission			,	,	,		,	
Crude	375	7/215 (3.3%)	0					
PS-adjusted	370	7/215 (3.3%)	0					

Codes:									
010011	O10919	01492	01493	01494	O1495	01500	O1502	01503	0151
010012	O1092	0152	O159	0161	O162	0163	O164	O165	0169
O10013	O1093	01422	O1042	01412	O1032	01402	O1022	0133	010119
O10019	0111	01423	O1043	01413	O1033	01403	O1023	0134	010211
01002	0112	01424	O10911	01414	O10411	01404	O10311	0135	010212
01003	0113	01425	O10912	01415	O10412	01405	O10312	0139	010213
010111	0114	O1490	O10913	01420	O10413	01410	O10313	O1400	
010112	0115	010113	0119	01012	O131	O1013	O132	O10219	

eTable 3. Hypertensive Disorder At Delivery Identified by the following ICD Coding Documented During Delivery Admission